Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug545 | Best Practice Wiki | 0.45 |
| drug421 | Azithromycin Wiki | 0.16 |
| drug1775 | Hydroxychloroquine Wiki | 0.10 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013577 | Syndrome NIH | 0.09 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
| D055371 | Acute Lung Injury NIH | 0.08 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
This phase I trial investigates the side effects of cord blood-derived mesenchymal stem cells (MSC) in treating patients with COVID-19 infection (COVID-19)-related acute respiratory distress syndrome (ARDS). MSCs are a type of stem cell that can be taken from umbilical cord blood and grown into many different cell types that can be used to treat cancer and other diseases. The MSCs being used for infusion in this trial are collected from healthy, unrelated donors and are stored and grown in a laboratory. Giving MSC infusions may help control the symptoms of ARDS.
Description: Serious adverse events with be comprised of grade 3 or 4 graft versus host disease or death and will be estimated and reported overall and by group, along with 95% confidence intervals.
Measure: Incidence of composite serious adverse events (Pilot) Time: Within 30 days of the first mesenchymal stem cell (MSC) infusionDescription: Will be estimated and reported with 95% confidence intervals.
Measure: Proportion of successfully extubated patients who present intubated on ventilator support (Pilot) Time: Up to day 30 post MSC infusionDescription: Will be estimated and reported with 95% confidence intervals.
Measure: Rate of successful progression to intubation in patients who require supplemental oxygen but who are otherwise able to breathe without assistance (Pilot) Time: Up to day 30 post MSC infusionDescription: Will be estimated and reported with 95% confidence intervals.
Measure: Overall survival rate (Pilot) Time: At day 30 post MSC infusionDescription: Will be estimated and reported with 95% confidence intervals.
Measure: Survival rate in patients who present intubated on ventilator support (Pilot) Time: At day 30 post MSC infusionDescription: Will be estimated and reported with 95% confidence intervals.
Measure: Survival rate in patients who require supplemental oxygen but who are otherwise able to breathe without assistance (Pilot) Time: At day 30 post MSC infusionDescription: Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Measure: Determine the treatment effect on clinical parameters, oxygenation and respiratory parameters Time: Up to day 30 post MSC infusionDescription: All grades of infusion-related adverse events will be summarized by grade and type.
Measure: Incidence of infusion-related adverse events (Pilot) Time: Up to day 30 post MSC infusionAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports